{
    "abstract": "Rabies virus remains an important burden of disease claiming an estimated 60,000 lives each year, mainly children, and having a huge economical and societal cost. Post-exposure prophylaxis (PEP) is highly effective, however in patients that present with neurological symptoms the case-fatality ratio is extremely high (>99%). During the last decades several attempts to identify potent and effective antivirals were made. Only a few of these demonstrated improvement in clinical signs in animal studies and none of the trials in humans showed significant efficacy. Here we explore novel opportunities to identify more potent anti-rabies molecules. In particular important progress has been made on antivirals against other Mononegavirales (paramyxoviruses, filoviruses) which should be an impetus to test and optimize these molecules towards anti-rabies virus therapies. Effective rabies antivirals for therapeutic use need to be molecules that can be dosed into the cerebrospinal fluid and that rapidly and potently block ongoing virus replication and as such stop the further spread of the virus. Antivirals for prophylactic use can also be envisaged and these should be able to prevent infection of peripheral nerve cells and should have the potential to replace the current anti-rabies immunoglobulins that are used in PEP.",
    "bib_entries": {
        "b0005": null,
        "b0010": {
            "authors": [
                {
                    "first": "Aaron",
                    "initial": "A.",
                    "last": "De Souza"
                },
                {
                    "first": "Shampur Narayan",
                    "initial": "S.N.",
                    "last": "Madhusudana"
                }
            ],
            "doi": "10.1016/j.jns.2014.02.013",
            "firstpage": "8",
            "issn": "0022510X",
            "lastpage": "14",
            "pmid": "24582283",
            "pub_year": 2014,
            "title": "Survival from rabies encephalitis",
            "volume": "339"
        },
        "b0015": {
            "authors": [
                {
                    "first": "Camila M.",
                    "initial": "C.M.",
                    "last": "Appolinario"
                },
                {
                    "first": "Alan C.",
                    "initial": "A.C.",
                    "last": "Jackson"
                }
            ],
            "doi": "10.3851/IMP2851",
            "firstpage": "1",
            "issn": "13596535",
            "lastpage": "10",
            "pmid": "25156675",
            "pub_year": 2015,
            "title": "Antiviral therapy for human rabies",
            "volume": "20"
        },
        "b0020": {
            "authors": [
                {
                    "first": "Henry",
                    "initial": "H.",
                    "last": "Wilde"
                },
                {
                    "first": "Thiravat",
                    "initial": "T.",
                    "last": "Hemachudha"
                }
            ],
            "doi": "10.1097/INF.0000000000000641",
            "firstpage": "678",
            "issn": "08913668",
            "lastpage": "679",
            "pmid": "25970115",
            "pub_year": 2015,
            "title": "The \"milwaukee Protocol\" for Treatment of Human Rabies Is No Longer Valid",
            "volume": "34"
        },
        "b0025": {
            "authors": [
                {
                    "first": "Yousuke",
                    "initial": "Y.",
                    "last": "Furuta"
                },
                {
                    "first": "Brian B.",
                    "initial": "B.B.",
                    "last": "Gowen"
                },
                {
                    "first": "Kazumi",
                    "initial": "K.",
                    "last": "Takahashi"
                },
                {
                    "first": "Kimiyasu",
                    "initial": "K.",
                    "last": "Shiraki"
                },
                {
                    "first": "Donald F.",
                    "initial": "D.F.",
                    "last": "Smee"
                },
                {
                    "first": "Dale L.",
                    "initial": "D.L.",
                    "last": "Barnard"
                }
            ],
            "doi": "10.1016/j.antiviral.2013.09.015",
            "firstpage": "446",
            "issn": "01663542",
            "lastpage": "454",
            "pmid": "24084488",
            "pub_year": 2013,
            "title": "Favipiravir (T-705), a novel viral RNA polymerase inhibitor",
            "volume": "100"
        },
        "b0030": {
            "authors": [
                {
                    "first": "Tatiana",
                    "initial": "T.",
                    "last": "Baranovich"
                },
                {
                    "first": "Sook San",
                    "initial": "S.S.",
                    "last": "Wong"
                },
                {
                    "first": "Jianling",
                    "initial": "J.",
                    "last": "Armstrong"
                },
                {
                    "first": "Henju",
                    "initial": "H.",
                    "last": "Marjuki"
                },
                {
                    "first": "Richard J.",
                    "initial": "R.J.",
                    "last": "Webby"
                },
                {
                    "first": "Robert G.",
                    "initial": "R.G.",
                    "last": "Webster"
                },
                {
                    "first": "Elena A.",
                    "initial": "E.A.",
                    "last": "Govorkova"
                }
            ],
            "doi": "10.1128/JVI.02346-12",
            "firstpage": "3741",
            "issn": "0022538X",
            "lastpage": "3751",
            "pub_year": 2013,
            "title": "T-705 (favipiravir) induces lethal mutagenesis in influenza a H1N1 viruses in vitro",
            "volume": "87"
        },
        "b0035": {
            "authors": [
                {
                    "first": "Kentaro",
                    "initial": "K.",
                    "last": "Yamada"
                },
                {
                    "first": "Kazuko",
                    "initial": "K.",
                    "last": "Noguchi"
                },
                {
                    "first": "Takashi",
                    "initial": "T.",
                    "last": "Komeno"
                },
                {
                    "first": "Yousuke",
                    "initial": "Y.",
                    "last": "Furuta"
                },
                {
                    "first": "Akira",
                    "initial": "A.",
                    "last": "Nishizono"
                }
            ],
            "doi": "10.1093/infdis/jiv586",
            "firstpage": "1253",
            "issn": "00221899",
            "lastpage": "1261",
            "pmid": "26655300",
            "pub_year": 2016,
            "title": "Efficacy of Favipiravir (T-705) in Rabies Postexposure Prophylaxis",
            "volume": "213"
        },
        "b0040": {
            "authors": [
                {
                    "first": "Jerome",
                    "initial": "J.",
                    "last": "Deval"
                },
                {
                    "first": "Jin",
                    "initial": "J.",
                    "last": "Hong"
                },
                {
                    "first": "Guangyi",
                    "initial": "G.",
                    "last": "Wang"
                },
                {
                    "first": "Josh",
                    "initial": "J.",
                    "last": "Taylor"
                },
                {
                    "first": "Lucas K.",
                    "initial": "L.K.",
                    "last": "Smith"
                },
                {
                    "first": "Amy",
                    "initial": "A.",
                    "last": "Fung"
                },
                {
                    "first": "Sarah K.",
                    "initial": "S.K.",
                    "last": "Stevens"
                },
                {
                    "first": "Hong",
                    "initial": "H.",
                    "last": "Liu"
                },
                {
                    "first": "Zhinan",
                    "initial": "Z.",
                    "last": "Jin"
                },
                {
                    "first": "Natalia",
                    "initial": "N.",
                    "last": "Dyatkina"
                },
                {
                    "first": "Marija",
                    "initial": "M.",
                    "last": "Prhavc"
                },
                {
                    "first": "Antitsa D.",
                    "initial": "A.D.",
                    "last": "Stoycheva"
                },
                {
                    "first": "Vladimir",
                    "initial": "V.",
                    "last": "Serebryany"
                },
                {
                    "first": "Jyanwei",
                    "initial": "J.",
                    "last": "Liu"
                },
                {
                    "first": "David B.",
                    "initial": "D.B.",
                    "last": "Smith"
                },
                {
                    "first": "Yuen",
                    "initial": "Y.",
                    "last": "Tam"
                },
                {
                    "first": "Qingling",
                    "initial": "Q.",
                    "last": "Zhang"
                },
                {
                    "first": "Martin L.",
                    "initial": "M.L.",
                    "last": "Moore"
                },
                {
                    "first": "Rachel",
                    "initial": "R.",
                    "last": "Fearns"
                },
                {
                    "first": "Sushmita M.",
                    "initial": "S.M.",
                    "last": "Chanda"
                },
                {
                    "first": "Lawrence M.",
                    "initial": "L.M.",
                    "last": "Blatt"
                },
                {
                    "first": "Julian A.",
                    "initial": "J.A.",
                    "last": "Symons"
                },
                {
                    "first": "Leo",
                    "initial": "L.",
                    "last": "Beigelman"
                }
            ],
            "doi": "10.1371/journal.ppat.1004995",
            "issn": "15537366",
            "pmid": "26098424",
            "pub_year": 2015,
            "title": "Molecular Basis for the Selective Inhibition of Respiratory Syncytial Virus RNA Polymerase by 2'-Fluoro-4'-Chloromethyl-Cytidine Triphosphate",
            "volume": "11"
        },
        "b0045": {
            "authors": [
                {
                    "first": "Michael O.",
                    "initial": "M.O.",
                    "last": "Clarke"
                },
                {
                    "first": "Richard",
                    "initial": "R.",
                    "last": "Mackman"
                },
                {
                    "first": "Daniel",
                    "initial": "D.",
                    "last": "Byun"
                },
                {
                    "first": "Hon",
                    "initial": "H.",
                    "last": "Hui"
                },
                {
                    "first": "Ona",
                    "initial": "O.",
                    "last": "Barauskas"
                },
                {
                    "first": "Gabriel",
                    "initial": "G.",
                    "last": "Birkus"
                },
                {
                    "first": "Byoung Kwon",
                    "initial": "B.K.",
                    "last": "Chun"
                },
                {
                    "first": "Edward",
                    "initial": "E.",
                    "last": "Doerffler"
                },
                {
                    "first": "Joy",
                    "initial": "J.",
                    "last": "Feng"
                },
                {
                    "first": "Kapil",
                    "initial": "K.",
                    "last": "Karki"
                },
                {
                    "first": "Gary",
                    "initial": "G.",
                    "last": "Lee"
                },
                {
                    "first": "Michel",
                    "initial": "M.",
                    "last": "Perron"
                },
                {
                    "first": "Dustin",
                    "initial": "D.",
                    "last": "Siegel"
                },
                {
                    "first": "Swami",
                    "initial": "S.",
                    "last": "Swaminathan"
                },
                {
                    "first": "William",
                    "initial": "W.",
                    "last": "Lee"
                }
            ],
            "doi": "10.1016/j.bmcl.2015.04.073",
            "firstpage": "2484",
            "issn": "0960894X",
            "lastpage": "2487",
            "pmid": "25978965",
            "pub_year": 2015,
            "title": "Discovery of \u03b2-D-2\u2032-deoxy-2\u2032-\u03b1-fluoro-4\u2032-\u03b1-cyano-5-aza-7,9-dideaza adenosine as a potent nucleoside inhibitor of respiratory syncytial virus with excellent selectivity over mitochondrial RNA and DNA polymerases",
            "volume": "25"
        },
        "b0050": {
            "authors": [
                {
                    "first": "Travis K.",
                    "initial": "T.K.",
                    "last": "Warren"
                },
                {
                    "first": "Jay",
                    "initial": "J.",
                    "last": "Wells"
                },
                {
                    "first": "Rekha G.",
                    "initial": "R.G.",
                    "last": "Panchal"
                },
                {
                    "first": "Kelly S.",
                    "initial": "K.S.",
                    "last": "Stuthman"
                },
                {
                    "first": "Nicole L.",
                    "initial": "N.L.",
                    "last": "Garza"
                },
                {
                    "first": "Sean A.",
                    "initial": "S.A.",
                    "last": "Van Tongeren"
                },
                {
                    "first": "Lian",
                    "initial": "L.",
                    "last": "Dong"
                },
                {
                    "first": "Cary J.",
                    "initial": "C.J.",
                    "last": "Retterer"
                },
                {
                    "first": "Brett P.",
                    "initial": "B.P.",
                    "last": "Eaton"
                },
                {
                    "first": "Gianluca",
                    "initial": "G.",
                    "last": "Pegoraro"
                },
                {
                    "first": "Shelley",
                    "initial": "S.",
                    "last": "Honnold"
                },
                {
                    "first": "Shanta",
                    "initial": "S.",
                    "last": "Bantia"
                },
                {
                    "first": "Pravin",
                    "initial": "P.",
                    "last": "Kotian"
                },
                {
                    "first": "Xilin",
                    "initial": "X.",
                    "last": "Chen"
                },
                {
                    "first": "Brian R.",
                    "initial": "B.R.",
                    "last": "Taubenheim"
                },
                {
                    "first": "Lisa S.",
                    "initial": "L.S.",
                    "last": "Welch"
                },
                {
                    "first": "Dena M.",
                    "initial": "D.M.",
                    "last": "Minning"
                },
                {
                    "first": "Yarlagadda S.",
                    "initial": "Y.S.",
                    "last": "Babu"
                },
                {
                    "first": "William P.",
                    "initial": "W.P.",
                    "last": "Sheridan"
                },
                {
                    "first": "Sina",
                    "initial": "S.",
                    "last": "Bavari"
                }
            ],
            "doi": "10.1038/nature13027",
            "firstpage": "402",
            "issn": "00280836",
            "lastpage": "405",
            "pmid": "24590073",
            "pub_year": 2014,
            "title": "Protection against filovirus diseases by a novel broad-spectrum nucleoside analogue BCX4430",
            "volume": "508"
        },
        "b0055": {
            "authors": [
                {
                    "first": "Dustin",
                    "initial": "D.",
                    "last": "Siegel"
                },
                {
                    "first": "Hon C.",
                    "initial": "H.C.",
                    "last": "Hui"
                },
                {
                    "first": "Edward",
                    "initial": "E.",
                    "last": "Doerffler"
                },
                {
                    "first": "Michael O.",
                    "initial": "M.O.",
                    "last": "Clarke"
                },
                {
                    "first": "Kwon",
                    "initial": "K.",
                    "last": "Chun"
                },
                {
                    "first": "Lijun",
                    "initial": "L.",
                    "last": "Zhang"
                },
                {
                    "first": "Sean",
                    "initial": "S.",
                    "last": "Neville"
                },
                {
                    "first": "Ernest",
                    "initial": "E.",
                    "last": "Carra"
                },
                {
                    "first": "Willard",
                    "initial": "W.",
                    "last": "Lew"
                },
                {
                    "first": "Bruce",
                    "initial": "B.",
                    "last": "Ross"
                },
                {
                    "first": "Queenie",
                    "initial": "Q.",
                    "last": "Wang"
                },
                {
                    "first": "Lydia",
                    "initial": "L.",
                    "last": "Wolfe"
                },
                {
                    "first": "Robert",
                    "initial": "R.",
                    "last": "Jordan"
                },
                {
                    "first": "Veronica",
                    "initial": "V.",
                    "last": "Soloveva"
                },
                {
                    "first": "John",
                    "initial": "J.",
                    "last": "Knox"
                },
                {
                    "first": "Jason",
                    "initial": "J.",
                    "last": "Perry"
                },
                {
                    "first": "Michel",
                    "initial": "M.",
                    "last": "Perron"
                },
                {
                    "first": "Kirsten M.",
                    "initial": "K.M.",
                    "last": "Stray"
                },
                {
                    "first": "Ona",
                    "initial": "O.",
                    "last": "Barauskas"
                },
                {
                    "first": "Joy Y.",
                    "initial": "J.Y.",
                    "last": "Feng"
                },
                {
                    "first": "Yili",
                    "initial": "Y.",
                    "last": "Xu"
                },
                {
                    "first": "Gary",
                    "initial": "G.",
                    "last": "Lee"
                },
                {
                    "first": "Arnold L.",
                    "initial": "A.L.",
                    "last": "Rheingold"
                },
                {
                    "first": "Adrian S.",
                    "initial": "A.S.",
                    "last": "Ray"
                },
                {
                    "first": "Roy",
                    "initial": "R.",
                    "last": "Bannister"
                },
                {
                    "first": "Robert",
                    "initial": "R.",
                    "last": "Strickley"
                },
                {
                    "first": "Swami",
                    "initial": "S.",
                    "last": "Swaminathan"
                },
                {
                    "first": "William A.",
                    "initial": "W.A.",
                    "last": "Lee"
                },
                {
                    "first": "Sina",
                    "initial": "S.",
                    "last": "Bavari"
                },
                {
                    "first": "Tomas",
                    "initial": "T.",
                    "last": "Cihlar"
                },
                {
                    "first": "Michael K.",
                    "initial": "M.K.",
                    "last": "Lo"
                },
                {
                    "first": "Travis K.",
                    "initial": "T.K.",
                    "last": "Warren"
                },
                {
                    "first": "Richard L.",
                    "initial": "R.L.",
                    "last": "Mackman"
                }
            ],
            "doi": "10.1021/acs.jmedchem.6b01594",
            "firstpage": "1648",
            "issn": "00222623",
            "lastpage": "1661",
            "pmid": "28124907",
            "pub_year": 2017,
            "title": "Discovery and Synthesis of a Phosphoramidate Prodrug of a Pyrrolo[2,1-f][triazin-4-amino] Adenine C-Nucleoside (GS-5734) for the Treatment of Ebola and Emerging Viruses",
            "volume": "60"
        },
        "b0060": {
            "authors": [
                {
                    "first": "Guillaume",
                    "initial": "G.",
                    "last": "Castel"
                },
                {
                    "first": "Mohamed",
                    "initial": "M.",
                    "last": "Cht\u00e9oui"
                },
                {
                    "first": "Gr\u00e9gory",
                    "initial": "G.",
                    "last": "Caignard"
                },
                {
                    "first": "Christophe",
                    "initial": "C.",
                    "last": "Pr\u00e9haud"
                },
                {
                    "first": "St\u00e9phanie",
                    "initial": "S.",
                    "last": "M\u00e9houas"
                },
                {
                    "first": "El\u00e9onore",
                    "initial": "E.",
                    "last": "R\u00e9al"
                },
                {
                    "first": "Corinne",
                    "initial": "C.",
                    "last": "Jallet"
                },
                {
                    "first": "Yves",
                    "initial": "Y.",
                    "last": "Jacob"
                },
                {
                    "first": "Rob W.H.",
                    "initial": "R.W.H.",
                    "last": "Ruigrok"
                },
                {
                    "first": "No\u00ebl",
                    "initial": "N.",
                    "last": "Tordo"
                }
            ],
            "doi": "10.1128/JVI.00977-09",
            "firstpage": "10808",
            "issn": "0022538X",
            "lastpage": "10820",
            "pmid": "19706704",
            "pub_year": 2009,
            "title": "Peptides that mimic the amino-terminal end of the rabies virus phosphoprotein have antiviral activity",
            "volume": "83"
        }
    },
    "body_text": [
        {
            "endOffset": 8858,
            "parents": [
                {
                    "id": "s0005",
                    "title": "Repurposing drugs approved for other indications"
                }
            ],
            "refoffsets": {
                "b0030": {
                    "endOffset": 8857,
                    "startOffset": 8854
                }
            },
            "secId": "s0010",
            "sentence": "It mimics a purine nucleotide analog that selectively inhibits the RNA-dependent RNA polymerase (RdRp) or causes lethal mutagenesis upon incorporation into the viral RNA [6].",
            "startOffset": 8684,
            "title": "Favipiravir"
        },
        {
            "endOffset": 15228,
            "parents": [],
            "secId": "s0050",
            "sentence": "Many challenges lay ahead as these molecules must be active in the CNS and they have to cope with a highly aggressive viral disease.",
            "startOffset": 15096,
            "title": "Conclusion"
        },
        {
            "endOffset": 15095,
            "parents": [],
            "secId": "s0050",
            "sentence": "The growth of knowledge in recent years regarding antivirals against other related viruses (paramyxoviruses, filoviruses) should be a stimulus to test and optimize these towards anti-rabies virus therapies.",
            "startOffset": 14889,
            "title": "Conclusion"
        },
        {
            "endOffset": 11591,
            "parents": [
                {
                    "id": "s0015",
                    "title": "Novel antivirals"
                },
                {
                    "id": "s0020",
                    "title": "Nucleosides in development for other negative strand RNA virus infections"
                }
            ],
            "refoffsets": {
                "b0045": {
                    "endOffset": 11590,
                    "startOffset": 11587
                }
            },
            "secId": "s0030",
            "sentence": "Another recent series of anti-RSV nucleosides are the 2\u2032d2\u2032F-nucleosides [9].",
            "startOffset": 11514,
            "title": "2\u2032d2\u2032F-nucleosides"
        },
        {
            "endOffset": 9635,
            "parents": [],
            "secId": "s0015",
            "sentence": "In addition to repurposing existing drugs, novel antiviral strategies have been explored for rabies.",
            "startOffset": 9535,
            "title": "Novel antivirals"
        },
        {
            "endOffset": 7897,
            "parents": [],
            "secId": "s0005",
            "sentence": "Two other FDA approved drugs with some in vitro anti-rabies activity are the N-methyl-D-aspartate (NMDA) receptor antagonist ketamine and amantadine (this last one is also approved for treatment of influenza).",
            "startOffset": 7688,
            "title": "Repurposing drugs approved for other indications"
        },
        {
            "endOffset": 14429,
            "parents": [
                {
                    "id": "s0015",
                    "title": "Novel antivirals"
                }
            ],
            "secId": "s0045",
            "sentence": "Detailed characterization of the binding mode of these peptides on their N proteins could therefore lead to a general principle of inhibiting rhabodoviruses and paramyxoviruses.",
            "startOffset": 14252,
            "title": "Disrupting the viral ribonucleoprotein complex"
        },
        {
            "endOffset": 10916,
            "parents": [
                {
                    "id": "s0015",
                    "title": "Novel antivirals"
                },
                {
                    "id": "s0020",
                    "title": "Nucleosides in development for other negative strand RNA virus infections"
                }
            ],
            "secId": "s0025",
            "sentence": "In vitro experiments also show that ALS-008112 is active on Parainfluenza virus and Vesicular stomatitis virus (VSV).",
            "startOffset": 10799,
            "title": "ALS-008176"
        },
        {
            "endOffset": 14889,
            "parents": [],
            "secId": "s0050",
            "sentence": "Until today, none of the antivirals with proven in vitro and/or in vivo activity, and that have been tested in humans, demonstrated good efficacy.",
            "startOffset": 14743,
            "title": "Conclusion"
        },
        {
            "endOffset": 10510,
            "parents": [
                {
                    "id": "s0015",
                    "title": "Novel antivirals"
                },
                {
                    "id": "s0020",
                    "title": "Nucleosides in development for other negative strand RNA virus infections"
                }
            ],
            "secId": "s0025",
            "sentence": "ALS-008176 is a nucleoside against RSV that has entered clinical trials.",
            "startOffset": 10438,
            "title": "ALS-008176"
        },
        {
            "endOffset": 8182,
            "parents": [],
            "secId": "s0005",
            "sentence": "A combination of ketamine and amantadine was explored in patients, together with other treatment interventions, in the so-called \u2018Milwaukee Protocol\u2019.",
            "startOffset": 8032,
            "title": "Repurposing drugs approved for other indications"
        },
        {
            "endOffset": 12854,
            "parents": [
                {
                    "id": "s0015",
                    "title": "Novel antivirals"
                },
                {
                    "id": "s0020",
                    "title": "Nucleosides in development for other negative strand RNA virus infections"
                }
            ],
            "secId": "s0040",
            "sentence": "In a rhesus monkey model of Ebola virus disease GS-5734 showed very good efficacy even when treatments were initiated three days after infection.",
            "startOffset": 12709,
            "title": "GS-5734"
        },
        {
            "endOffset": 11234,
            "parents": [
                {
                    "id": "s0015",
                    "title": "Novel antivirals"
                },
                {
                    "id": "s0020",
                    "title": "Nucleosides in development for other negative strand RNA virus infections"
                }
            ],
            "refoffsets": {
                "b0040": {
                    "endOffset": 11233,
                    "startOffset": 11230
                }
            },
            "secId": "s0025",
            "sentence": "No activity was detected on negative strand RNA viruses beyond the Paramyxo- and Rhabdoviridae families, nor was activity noted against any of the tested positive strand RNA viruses [8].",
            "startOffset": 11048,
            "title": "ALS-008176"
        },
        {
            "endOffset": 13372,
            "parents": [
                {
                    "id": "s0015",
                    "title": "Novel antivirals"
                }
            ],
            "secId": "s0045",
            "sentence": "The rabies RNP is built around the N-protein that oligomerizes to form a helix around which the viral RNA is wrapped.",
            "startOffset": 13255,
            "title": "Disrupting the viral ribonucleoprotein complex"
        },
        {
            "endOffset": 13710,
            "parents": [
                {
                    "id": "s0015",
                    "title": "Novel antivirals"
                }
            ],
            "secId": "s0045",
            "sentence": "The P-protein allows efficient and specific recognition of the RNP template by the RdRp and subsequent RNA polymerization.",
            "startOffset": 13588,
            "title": "Disrupting the viral ribonucleoprotein complex"
        },
        {
            "endOffset": 7687,
            "parents": [],
            "secId": "s0005",
            "sentence": "Ribavirin and interferon-alpha are broad-spectrum antivirals that have significant in vitro activity against rabies but in vivo experiments and treatment of several human patients with rabies infection did not show any beneficial activity.",
            "startOffset": 7448,
            "title": "Repurposing drugs approved for other indications"
        },
        {
            "endOffset": 9251,
            "parents": [
                {
                    "id": "s0005",
                    "title": "Repurposing drugs approved for other indications"
                }
            ],
            "secId": "s0010",
            "sentence": "In vivo experiments showed that it, under conditions of early start of treatment, improves the clinical signs and survival rate of mice infected intramuscularly.",
            "startOffset": 9090,
            "title": "Favipiravir"
        },
        {
            "endOffset": 9732,
            "parents": [],
            "refoffsets": {
                "b0015": {
                    "endOffset": 9723,
                    "startOffset": 9720
                }
            },
            "secId": "s0015",
            "sentence": "These have been reviewed extensively in the recent paper by Appolinario and Jackson [3] as well.",
            "startOffset": 9636,
            "title": "Novel antivirals"
        },
        {
            "endOffset": 8615,
            "parents": [
                {
                    "id": "s0005",
                    "title": "Repurposing drugs approved for other indications"
                }
            ],
            "secId": "s0010",
            "sentence": "Intracellular host enzymes convert favipiravir to its active form favipiravir-4-ribofuranosyl-5-triphosphate (T-705-RTP).",
            "startOffset": 8494,
            "title": "Favipiravir"
        },
        {
            "endOffset": 14619,
            "parents": [],
            "secId": "s0050",
            "sentence": "Antivirals for rabies are expected to have a major impact if they could block and eliminate viral replication in patients that show the first neurological symptoms of the disease.",
            "startOffset": 14440,
            "title": "Conclusion"
        },
        {
            "endOffset": 11321,
            "parents": [
                {
                    "id": "s0015",
                    "title": "Novel antivirals"
                },
                {
                    "id": "s0020",
                    "title": "Nucleosides in development for other negative strand RNA virus infections"
                }
            ],
            "secId": "s0025",
            "sentence": "As indicated above ALS-008176 is a prodrug that needs metabolisation to become active.",
            "startOffset": 11235,
            "title": "ALS-008176"
        },
        {
            "endOffset": 13254,
            "parents": [
                {
                    "id": "s0015",
                    "title": "Novel antivirals"
                }
            ],
            "secId": "s0045",
            "sentence": "A unique approach to investigate a potential Rabies virus antiviral strategy was the study of peptides that disrupt the interactions between the viral ribonucleoprotein complex (RNP) and the L- and P-protein.",
            "startOffset": 13046,
            "title": "Disrupting the viral ribonucleoprotein complex"
        },
        {
            "endOffset": 11047,
            "parents": [
                {
                    "id": "s0015",
                    "title": "Novel antivirals"
                },
                {
                    "id": "s0020",
                    "title": "Nucleosides in development for other negative strand RNA virus infections"
                }
            ],
            "secId": "s0025",
            "sentence": "The EC50 on VSV was reported as 3.4 \u00b5M, which is \u223c20-fold less active as on RSV but still with a good selectivity (CC50 > 100 \u00b5M).",
            "startOffset": 10917,
            "title": "ALS-008176"
        },
        {
            "endOffset": 12997,
            "parents": [
                {
                    "id": "s0015",
                    "title": "Novel antivirals"
                },
                {
                    "id": "s0020",
                    "title": "Nucleosides in development for other negative strand RNA virus infections"
                }
            ],
            "secId": "s0040",
            "sentence": "Given the broad-spectrum activity on filoviruses and paramyxoviruses, this nucleotide-prodrug may also inhibit rhabdoviruses including rabies.",
            "startOffset": 12855,
            "title": "GS-5734"
        },
        {
            "endOffset": 11977,
            "parents": [
                {
                    "id": "s0015",
                    "title": "Novel antivirals"
                },
                {
                    "id": "s0020",
                    "title": "Nucleosides in development for other negative strand RNA virus infections"
                }
            ],
            "refoffsets": {
                "b0050": {
                    "endOffset": 11976,
                    "startOffset": 11972
                }
            },
            "secId": "s0035",
            "sentence": "BCX4430 is a nucleoside with broad-spectrum activity against picorna-, flavi-, orthomyxo-, paramyxo- and filoviruses in vitro [10].",
            "startOffset": 11846,
            "title": "BCX4430"
        },
        {
            "endOffset": 11491,
            "parents": [
                {
                    "id": "s0015",
                    "title": "Novel antivirals"
                },
                {
                    "id": "s0020",
                    "title": "Nucleosides in development for other negative strand RNA virus infections"
                }
            ],
            "secId": "s0025",
            "sentence": "In particular, the phosphorylation to the nucleoside-triphosphate is a step that can be cell type dependent and that should be explored in neurons in the case of rabies.",
            "startOffset": 11322,
            "title": "ALS-008176"
        },
        {
            "endOffset": 13808,
            "parents": [
                {
                    "id": "s0015",
                    "title": "Novel antivirals"
                }
            ],
            "secId": "s0045",
            "sentence": "In this way, P permits the continued contact between the RdRp and the RNP as the RdRp progresses.",
            "startOffset": 13711,
            "title": "Disrupting the viral ribonucleoprotein complex"
        },
        {
            "endOffset": 10333,
            "parents": [
                {
                    "id": "s0015",
                    "title": "Novel antivirals"
                }
            ],
            "secId": "s0020",
            "sentence": "However, in recent years several nucleosides with activity against Respiratory syncytial virus (RSV) and Ebola virus have been discovered.",
            "startOffset": 10195,
            "title": "Nucleosides in development for other negative strand RNA virus infections"
        },
        {
            "endOffset": 14251,
            "parents": [
                {
                    "id": "s0015",
                    "title": "Novel antivirals"
                }
            ],
            "secId": "s0045",
            "sentence": "It is interesting to note that corresponding P-peptides have previously also been shown to inhibit replication of RSV and Nipah virus.",
            "startOffset": 14117,
            "title": "Disrupting the viral ribonucleoprotein complex"
        },
        {
            "endOffset": 12232,
            "parents": [
                {
                    "id": "s0015",
                    "title": "Novel antivirals"
                },
                {
                    "id": "s0020",
                    "title": "Nucleosides in development for other negative strand RNA virus infections"
                }
            ],
            "secId": "s0035",
            "sentence": "BCX4430 has shown efficacy against several virus infection in animal models and is currently in development for the treatment of Ebola virus disease.",
            "startOffset": 12083,
            "title": "BCX4430"
        },
        {
            "endOffset": 9366,
            "parents": [
                {
                    "id": "s0005",
                    "title": "Repurposing drugs approved for other indications"
                }
            ],
            "secId": "s0010",
            "sentence": "If the start of favipiravir treatment is delayed for 1 or 2 days no significant protective effect can be observed.",
            "startOffset": 9252,
            "title": "Favipiravir"
        },
        {
            "endOffset": 12082,
            "parents": [
                {
                    "id": "s0015",
                    "title": "Novel antivirals"
                },
                {
                    "id": "s0020",
                    "title": "Nucleosides in development for other negative strand RNA virus infections"
                }
            ],
            "secId": "s0035",
            "sentence": "Unfortunately, its activity against rhabdoviruses such as VSV or Rabies virus has not yet been reported.",
            "startOffset": 11978,
            "title": "BCX4430"
        },
        {
            "endOffset": 15575,
            "parents": [],
            "secId": "s0055",
            "sentence": "This work was supported by the European Union Seventh Framework Program under the ASKLEPIOS grant agreement (Grant No. 602825).",
            "startOffset": 15448,
            "title": "Funding"
        },
        {
            "endOffset": 10798,
            "parents": [
                {
                    "id": "s0015",
                    "title": "Novel antivirals"
                },
                {
                    "id": "s0020",
                    "title": "Nucleosides in development for other negative strand RNA virus infections"
                }
            ],
            "secId": "s0025",
            "sentence": "Biochemical studies revealed that ALS-008112-5\u2032-triphosphate is a potent and selective inhibitor of RSV RNA-dependent RNA polymerase activity (Ki of 0.09 \u00b5M), via a classic chain termination mechanism.",
            "startOffset": 10597,
            "title": "ALS-008176"
        },
        {
            "endOffset": 8493,
            "parents": [
                {
                    "id": "s0005",
                    "title": "Repurposing drugs approved for other indications"
                }
            ],
            "refoffsets": {
                "b0025": {
                    "endOffset": 8492,
                    "startOffset": 8489
                }
            },
            "secId": "s0010",
            "sentence": "Another more recently approved drug that has been explored in rabies infection is favipiravir (T-705), a broad spectrum antiviral [5].",
            "startOffset": 8359,
            "title": "Favipiravir"
        },
        {
            "endOffset": 8683,
            "parents": [
                {
                    "id": "s0005",
                    "title": "Repurposing drugs approved for other indications"
                }
            ],
            "secId": "s0010",
            "sentence": "The mechanism of action of T-705-RTP remains a topic of discussion.",
            "startOffset": 8616,
            "title": "Favipiravir"
        },
        {
            "endOffset": 12708,
            "parents": [
                {
                    "id": "s0015",
                    "title": "Novel antivirals"
                },
                {
                    "id": "s0020",
                    "title": "Nucleosides in development for other negative strand RNA virus infections"
                }
            ],
            "secId": "s0040",
            "sentence": "It has broad-spectrum antiviral activity against several pathogenic RNA viruses, including filoviruses, arenaviruses, paramyxoviruses and coronaviruses.",
            "startOffset": 12556,
            "title": "GS-5734"
        },
        {
            "endOffset": 12435,
            "parents": [
                {
                    "id": "s0015",
                    "title": "Novel antivirals"
                },
                {
                    "id": "s0020",
                    "title": "Nucleosides in development for other negative strand RNA virus infections"
                }
            ],
            "secId": "s0035",
            "sentence": "Given the broad-spectrum and the good efficacy in several animal models of virus disease, including infections with negative strand viruses, this molecule is a candidate to explore in rabies infections.",
            "startOffset": 12233,
            "title": "BCX4430"
        },
        {
            "endOffset": 10596,
            "parents": [
                {
                    "id": "s0015",
                    "title": "Novel antivirals"
                },
                {
                    "id": "s0020",
                    "title": "Nucleosides in development for other negative strand RNA virus infections"
                }
            ],
            "secId": "s0025",
            "sentence": "ALS-008176, is the ester-prodrug of ALS-008112 which is a cytidine nucleoside analog.",
            "startOffset": 10511,
            "title": "ALS-008176"
        },
        {
            "endOffset": 9791,
            "parents": [],
            "secId": "s0015",
            "sentence": "In the following, we highlight some additional strategies.",
            "startOffset": 9733,
            "title": "Novel antivirals"
        },
        {
            "endOffset": 12555,
            "parents": [
                {
                    "id": "s0015",
                    "title": "Novel antivirals"
                },
                {
                    "id": "s0020",
                    "title": "Nucleosides in development for other negative strand RNA virus infections"
                }
            ],
            "refoffsets": {
                "b0055": {
                    "endOffset": 12554,
                    "startOffset": 12550
                }
            },
            "secId": "s0040",
            "sentence": "GS-5734 is a monophosphate prodrug that was discovered in a recent anti-Ebola virus screening campaign [11].",
            "startOffset": 12447,
            "title": "GS-5734"
        },
        {
            "endOffset": 9518,
            "parents": [
                {
                    "id": "s0005",
                    "title": "Repurposing drugs approved for other indications"
                }
            ],
            "secId": "s0010",
            "sentence": "This indicates that favipiravir might be ineffective against viruses located within the nervous systems and may be only effective before neuroinvasion.",
            "startOffset": 9367,
            "title": "Favipiravir"
        },
        {
            "endOffset": 14117,
            "parents": [
                {
                    "id": "s0015",
                    "title": "Novel antivirals"
                }
            ],
            "secId": "s0045",
            "sentence": "Peptides derived from this domain where shown to interact directly with the N- and L-protein and to be able to block rabies virus replication in cell culture.",
            "startOffset": 13959,
            "title": "Disrupting the viral ribonucleoprotein complex"
        },
        {
            "endOffset": 15441,
            "parents": [],
            "secId": "s0050",
            "sentence": "But given the successes of antivirals on other aggressive viral infections (Herpes, HIV, HCV, \u2026) we believe that a similarly resolute effort must be undertaken in order to develop effective anti-rabies therapies.",
            "startOffset": 15229,
            "title": "Conclusion"
        },
        {
            "endOffset": 14742,
            "parents": [],
            "secId": "s0050",
            "sentence": "In addition, effective antivirals might have the capacity to replace the use of RIGs of which the availability is limited.",
            "startOffset": 14620,
            "title": "Conclusion"
        },
        {
            "endOffset": 8988,
            "parents": [
                {
                    "id": "s0005",
                    "title": "Repurposing drugs approved for other indications"
                }
            ],
            "refoffsets": {
                "b0025": {
                    "endOffset": 8987,
                    "startOffset": 8984
                }
            },
            "secId": "s0010",
            "sentence": "Favipiravir is currently approved for treatment against influenza in Japan, and is in clinical development the United States [5].",
            "startOffset": 8859,
            "title": "Favipiravir"
        },
        {
            "endOffset": 8345,
            "parents": [],
            "refoffsets": {
                "b0020": {
                    "endOffset": 8344,
                    "startOffset": 8341
                }
            },
            "secId": "s0005",
            "sentence": "While this protocol had high coverage in the media as the first patient treated recovered, it has not been repeatable and is now considered to be ineffective [4].",
            "startOffset": 8183,
            "title": "Repurposing drugs approved for other indications"
        },
        {
            "endOffset": 10423,
            "parents": [
                {
                    "id": "s0015",
                    "title": "Novel antivirals"
                }
            ],
            "secId": "s0020",
            "sentence": "As discussed below these are excellent candidates to be explored further on Rabies virus.",
            "startOffset": 10334,
            "title": "Nucleosides in development for other negative strand RNA virus infections"
        },
        {
            "endOffset": 13958,
            "parents": [
                {
                    "id": "s0015",
                    "title": "Novel antivirals"
                }
            ],
            "refoffsets": {
                "b0060": {
                    "endOffset": 13957,
                    "startOffset": 13953
                }
            },
            "secId": "s0045",
            "sentence": "As the N-terminal domain of the P-protein interacts with both the N- and L-protein it was chosen as a tool to explore a novel antiviral strategy [12].",
            "startOffset": 13808,
            "title": "Disrupting the viral ribonucleoprotein complex"
        },
        {
            "endOffset": 13587,
            "parents": [
                {
                    "id": "s0015",
                    "title": "Novel antivirals"
                }
            ],
            "secId": "s0045",
            "sentence": "Viral RNA synthesis is mediated by the viral Phospho- (P) protein, which is a multifunctional protein that interacts with L and N.",
            "startOffset": 13457,
            "title": "Disrupting the viral ribonucleoprotein complex"
        },
        {
            "endOffset": 11834,
            "parents": [
                {
                    "id": "s0015",
                    "title": "Novel antivirals"
                },
                {
                    "id": "s0020",
                    "title": "Nucleosides in development for other negative strand RNA virus infections"
                }
            ],
            "secId": "s0030",
            "sentence": "These have not yet been characterized in animal studies nor has their activity on other negative strand RNA viruses been reported, but given their activity on RSV it may be worthwhile to explore these molecules for anti-Rabies virus activity.",
            "startOffset": 11592,
            "title": "2\u2032d2\u2032F-nucleosides"
        },
        {
            "endOffset": 13456,
            "parents": [
                {
                    "id": "s0015",
                    "title": "Novel antivirals"
                }
            ],
            "secId": "s0045",
            "sentence": "This RNP is the template for transcription and replication by the RdRp (L protein).",
            "startOffset": 13373,
            "title": "Disrupting the viral ribonucleoprotein complex"
        },
        {
            "endOffset": 10194,
            "parents": [
                {
                    "id": "s0015",
                    "title": "Novel antivirals"
                }
            ],
            "secId": "s0020",
            "sentence": "While nucleosides, that selectively inhibit the polymerase of viruses, are approved for the treatment of Herpes virus, Human immunodeficiency virus (HIV), Hepatitis C virus (HCV) and Hepatitis B virus (HBV), the discovery of nucleosides that specifically inhibit negative strand RNA virus polymerases has been more challenging.",
            "startOffset": 9867,
            "title": "Nucleosides in development for other negative strand RNA virus infections"
        },
        {
            "endOffset": 9089,
            "parents": [
                {
                    "id": "s0005",
                    "title": "Repurposing drugs approved for other indications"
                }
            ],
            "refoffsets": {
                "b0035": {
                    "endOffset": 9015,
                    "startOffset": 9012
                }
            },
            "secId": "s0010",
            "sentence": "Recently Yamada et al. [7] showed that favipiravir also has antiviral activity against Rabies virus.",
            "startOffset": 8989,
            "title": "Favipiravir"
        },
        {
            "endOffset": 8031,
            "parents": [],
            "secId": "s0005",
            "sentence": "Ketamine showed some effect on rabies infection in animal studies while for amantadine efficacy in animals could not be demonstrated.",
            "startOffset": 7898,
            "title": "Repurposing drugs approved for other indications"
        },
        {
            "endOffset": 15704,
            "parents": [],
            "secId": "s0055",
            "sentence": "The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.",
            "startOffset": 15576,
            "title": "Funding"
        }
    ],
    "docId": "S0264410X17318121",
    "metadata": {
        "asjc": [
            "1313",
            "2400",
            "2725",
            "2739",
            "3400"
        ],
        "authors": [
            {
                "email": "dirk.jochmans@kuleuven.be",
                "first": "Dirk",
                "initial": "D.",
                "last": "Jochmans"
            },
            {
                "email": null,
                "first": "J.",
                "initial": "J.",
                "last": "Neyts"
            }
        ],
        "doi": "10.1016/j.vaccine.2017.12.051",
        "firstpage": "4660",
        "issn": "0264410X",
        "keywords": [
            "Antivirals",
            "Rabies"
        ],
        "lastpage": "4662",
        "openaccess": "Full",
        "pub_year": 2019,
        "subjareas": [
            "BIOC",
            "IMMU",
            "MEDI",
            "VETE"
        ],
        "title": "The path towards effective antivirals against rabies"
    }
}